{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,27]],"date-time":"2025-10-27T04:53:07Z","timestamp":1761540787290},"reference-count":29,"publisher":"Elsevier BV","issue":"9","license":[{"start":{"date-parts":[[2007,11,1]],"date-time":"2007-11-01T00:00:00Z","timestamp":1193875200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["The American Journal of Cardiology"],"published-print":{"date-parts":[[2007,11]]},"DOI":"10.1016\/j.amjcard.2007.06.024","type":"journal-article","created":{"date-parts":[[2007,8,17]],"date-time":"2007-08-17T11:08:24Z","timestamp":1187348904000},"page":"1376-1382","source":"Crossref","is-referenced-by-count":13,"title":["Effectiveness and Safety of Reduced-Dose Enoxaparin in Non\u2013ST-Segment Elevation Acute Coronary Syndrome Followed by Antiplatelet Therapy Alone for Percutaneous Coronary Intervention"],"prefix":"10.1016","volume":"100","author":[{"given":"Scott J.","family":"Denardo","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Keith E.","family":"Davis","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"James E.","family":"Tcheng","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.amjcard.2007.06.024_bib1","year":"2002"},{"key":"10.1016\/j.amjcard.2007.06.024_bib2","year":"2005"},{"key":"10.1016\/j.amjcard.2007.06.024_bib3","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1161\/01.CIR.97.3.251","article-title":"Platelet activation with unfractionated heparin at therapeutic concentrations and comparisons with a low-molecular-weight heparin and with a direct thrombin inhibitor","volume":"97","author":"Xiao","year":"1998","journal-title":"Circulation"},{"key":"10.1016\/j.amjcard.2007.06.024_bib4","doi-asserted-by":"crossref","first-page":"2083","DOI":"10.1016\/j.jacc.2003.05.014","article-title":"Recurrent cardiac ischemic events early after discontinuation of short-term heparin treatment in acute coronary syndromes","volume":"42","author":"Bijsterveld","year":"2003","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.amjcard.2007.06.024_bib5","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1056\/NEJM199207163270301","article-title":"Reactivation of unstable angina after the discontinuation of heparin","volume":"327","author":"Theroux","year":"1992","journal-title":"N Engl J Med"},{"key":"10.1016\/j.amjcard.2007.06.024_bib6","doi-asserted-by":"crossref","first-page":"434","DOI":"10.1016\/S0002-8703(96)90520-7","article-title":"Transient thrombotic state after abrupt discontinuation of heparin in percutaneous coronary angioplasty","volume":"131","author":"Smith","year":"1996","journal-title":"Am Heart J"},{"key":"10.1016\/j.amjcard.2007.06.024_bib7","first-page":"45","article-title":"Enoxaparin vs unfractionated heparin in high-risk patients with non-ST-segment elevation acute coronary syndromes managed with an intended early invasive strategy: primary results of the SYNERGY randomized trial","volume":"292","year":"2004","journal-title":"JAMA"},{"key":"10.1016\/j.amjcard.2007.06.024_bib8","doi-asserted-by":"crossref","first-page":"3108","DOI":"10.1001\/jama.294.24.3108","article-title":"Excess dosing of antiplatelet and antithrombin agents in the treatment of non-ST-segment elevation acute coronary syndromes","volume":"294","author":"Alexander","year":"2005","journal-title":"JAMA"},{"key":"10.1016\/j.amjcard.2007.06.024_bib9","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1016\/S0002-9149(03)00637-4","article-title":"Relation between the degree of procedural anticoagulation and complications after coronary stent implantation","volume":"92","author":"Ashby","year":"2003","journal-title":"Am J Cardiol"},{"key":"10.1016\/j.amjcard.2007.06.024_bib10","doi-asserted-by":"crossref","first-page":"1449","DOI":"10.1016\/S0735-1097(98)00134-X","article-title":"Heparin-induced thrombocytopenia","volume":"31","author":"Brieger","year":"1998","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.amjcard.2007.06.024_bib11","doi-asserted-by":"crossref","first-page":"138","DOI":"10.1016\/j.ahj.2004.06.002","article-title":"Elective percutaneous coronary intervention using broad-spectrum antiplatelet therapy (eptifibatide, clopidogrel, and aspirin) alone, without scheduled unfractionated heparin or other antithrombin therapy","volume":"149","author":"Denardo","year":"2005","journal-title":"Am Heart J"},{"key":"10.1016\/j.amjcard.2007.06.024_bib12","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1016\/S0002-9343(99)00416-7","article-title":"Redefining medical treatment in the management of unstable angina","volume":"108","author":"Braunwald","year":"2000","journal-title":"Am J Med"},{"key":"10.1016\/j.amjcard.2007.06.024_bib13","first-page":"23192","article-title":"Belmont Report: ethical principles and guidelines for the protection of human subjects of research","volume":"44","year":"1979","journal-title":"Fed Regist"},{"key":"10.1016\/j.amjcard.2007.06.024_bib14","doi-asserted-by":"crossref","first-page":"162","DOI":"10.1016\/j.jacc.2003.08.033","volume":"43","author":"Dalby","year":"2004","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.amjcard.2007.06.024_bib15","first-page":"3","article-title":"Prevention of venous thromboembolism: international consensus statement (guidelines according to clinical evidence)","volume":"16","year":"1997","journal-title":"Int Angiol"},{"key":"10.1016\/j.amjcard.2007.06.024_bib16","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/0735-1097(88)90158-1","article-title":"Thrombolysis In Myocardial Infarction (TIMI) Trial\u2014phase I: hemorrhagic manifestations and changes in plasma fibrinogen and the fibrinolytic system in patients with recombinant tissue plasminogen activator and streptokinase","volume":"11","author":"Rao","year":"1988","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.amjcard.2007.06.024_bib17","first-page":"188","article-title":"Primer of Biostatistics","author":"Glantz","year":"1992"},{"key":"10.1016\/j.amjcard.2007.06.024_bib18","doi-asserted-by":"crossref","first-page":"1095","DOI":"10.1056\/NEJMoa044259","article-title":"Early invasive versus selectively invasive management for acute coronary syndromes","volume":"353","author":"de Winter","year":"2005","journal-title":"N Engl J Med"},{"key":"10.1016\/j.amjcard.2007.06.024_bib19","doi-asserted-by":"crossref","first-page":"1593","DOI":"10.1001\/jama.290.12.1593","article-title":"Evaluation of prolonged antithrombotic pretreatment (\u201ccooling-off\u201d strategy) before intervention in patients with unstable coronary syndromes","volume":"290","author":"Neumann","year":"2003","journal-title":"JAMA"},{"key":"10.1016\/j.amjcard.2007.06.024_bib20","doi-asserted-by":"crossref","first-page":"1688","DOI":"10.1016\/j.ehj.2004.06.028","article-title":"Enoxaparin versus unfractionated heparin in patients treated with tirofiban, aspirin and an early conservative initial management strategy: results from the A phase of the A-to-Z trial","volume":"25","author":"de Lemos","year":"2004","journal-title":"Eur Heart J"},{"key":"10.1016\/j.amjcard.2007.06.024_bib21","doi-asserted-by":"crossref","first-page":"1429","DOI":"10.1016\/S0140-6736(96)10452-9","article-title":"Randomised placebo-controlled trial of abciximab before, during and after coronary intervention in refractory unstable angina: the CAPTURE study","volume":"349","year":"1997","journal-title":"Lancet"},{"key":"10.1016\/j.amjcard.2007.06.024_bib22","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/S0002-9149(02)02988-0","article-title":"Efficacy and safety of minimal dose (\u22641000 units) unfractionated heparin with abciximab in percutaneous coronary intervention","volume":"91","author":"Denardo","year":"2003","journal-title":"Am J Cardiol"},{"key":"10.1016\/j.amjcard.2007.06.024_bib23","doi-asserted-by":"crossref","first-page":"2347","DOI":"10.1161\/01.CIR.0000017635.82128.8C","article-title":"Impact of clinical syndrome acuity on the differential response to 2 glycoprotein IIb\/IIIa inhibitors in patients undergoing coronary stenting: the TARGET trial","volume":"105","author":"Stone","year":"2002","journal-title":"Circulation"},{"key":"10.1016\/j.amjcard.2007.06.024_bib24","doi-asserted-by":"crossref","first-page":"628","DOI":"10.1016\/S0002-8703(03)00165-0","article-title":"Combining enoxaparin and glycoprotein IIb\/IIIa antagonists for the treatment of acute coronary syndromes: final results of the National Investigators Collaborating on Enoxaparin-3 (NICE-3) study","volume":"146","author":"Ferguson","year":"2003","journal-title":"Am Heart J"},{"key":"10.1016\/j.amjcard.2007.06.024_bib25","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1016\/j.ahj.2005.09.007","article-title":"Outcomes of patients with acute coronary syndromes who are treated with bivalirudin during percutaneous coronary intervention: an analysis from the Randomized Evaluation in PCI Linking Angiomax to Reduced Clinical Events (REPLACE-2) trial","volume":"152","author":"Rajagopal","year":"2006","journal-title":"Am Heart J"},{"key":"10.1016\/j.amjcard.2007.06.024_bib26","doi-asserted-by":"crossref","first-page":"969","DOI":"10.1016\/S0002-9149(01)01972-5","article-title":"Effect of eptifibatide on angiographic complications during percutaneous coronary intervention in the IMPACT (Integrilin to Minimize Platelet Aggregation and Coronary Thrombosis) II trial","volume":"88","author":"Blankenship","year":"2001","journal-title":"Am J Cardiol"},{"key":"10.1016\/j.amjcard.2007.06.024_bib27","doi-asserted-by":"crossref","first-page":"916","DOI":"10.1016\/S0002-9149(02)02653-X","article-title":"Effect of abciximab on angiographic complications during percutaneous coronary stenting in the Evaluation of Platelet IIb\/IIIa Inhibition in Stenting Trial (EPISTENT)","volume":"90","author":"Islam","year":"2002","journal-title":"Am J Cardiol"},{"key":"10.1016\/j.amjcard.2007.06.024_bib28","doi-asserted-by":"crossref","first-page":"1464","DOI":"10.1056\/NEJMoa055443","article-title":"Comparison of fondaparinux and enoxaparin in acute coronary syndromes","volume":"354","year":"2006","journal-title":"N Engl J Med"},{"key":"10.1016\/j.amjcard.2007.06.024_bib29","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1002\/ccd.10726","article-title":"Reliable anticoagulation with enoxaparin in patients undergoing percutaneous coronary intervention: the Pharmacokinetics of Enoxaparin in PCI (PEPCI) study","volume":"61","author":"Martin","year":"2004","journal-title":"Catheter Cardiovasc Interv"}],"container-title":["The American Journal of Cardiology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0002914907014270?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0002914907014270?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2019,1,5]],"date-time":"2019-01-05T03:56:25Z","timestamp":1546660585000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0002914907014270"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2007,11]]},"references-count":29,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2007,11]]}},"alternative-id":["S0002914907014270"],"URL":"https:\/\/doi.org\/10.1016\/j.amjcard.2007.06.024","relation":{},"ISSN":["0002-9149"],"issn-type":[{"value":"0002-9149","type":"print"}],"subject":[],"published":{"date-parts":[[2007,11]]}}}